Cargando…
1593. Switch to DOVATO in Patients Suppressed on Biktarvy (The SOUND Study), week 48 interim analysis
BACKGROUND: Dolutegravir/lamivudine(DTG/3TC) is a complete regimen, approved by the FDA for the treatment of HIV-1 infection in treatment-naïve or virologically suppressed patients with no prior virologic failure or resistance to DTG/3TC. The SOUND study evaluated virologically suppressed (< 50 c...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678138/ http://dx.doi.org/10.1093/ofid/ofad500.1428 |